Stockscreener 앱 받기
51.07
0.22%
0.11
시간 외 거래:
51.07
전일 마감가:
$50.96
열려 있는:
$50.94
하루 거래량:
719.04K
Relative Volume:
0.89
시가총액:
$3.17B
수익:
$45.48M
순이익/손실:
$169.95M
주가수익비율:
19.49
EPS:
2.62
순현금흐름:
$230.85M
1주 성능:
-5.13%
1개월 성능:
+2.76%
6개월 성능:
+31.35%
1년 성능:
+37.36%
1일 변동 폭
$50.48
$51.41
1주일 범위
$50.48
$54.81
52주 변동 폭
$33.31
$60.60
Protagonist Therapeutics Inc Stock (PTGX) Company Profile
명칭
Protagonist Therapeutics Inc
전화
(510) 474-0170
주소
7707 GATEWAY BLVD., SUITE 140, NEWARK, CA
PTGX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PTGX
Protagonist Therapeutics Inc
|
51.07 | 3.34B | 45.48M | 169.95M | 230.85M | 2.62 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Protagonist Therapeutics Inc Stock (PTGX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-17 | 개시 | Citigroup | Buy |
| 2024-12-06 | 개시 | BMO Capital Markets | Outperform |
| 2024-12-06 | 개시 | Goldman | Neutral |
| 2024-11-05 | 개시 | Wedbush | Outperform |
| 2024-09-24 | 개시 | TD Cowen | Buy |
| 2024-09-09 | 개시 | Truist | Buy |
| 2023-10-30 | 개시 | CapitalOne | Overweight |
| 2023-05-25 | 재개 | Jefferies | Buy |
| 2022-08-25 | 개시 | JMP Securities | Mkt Outperform |
| 2022-02-11 | 개시 | BTIG Research | Buy |
| 2021-10-12 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-10-11 | 업그레이드 | Northland Capital | Market Perform → Outperform |
| 2021-09-20 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-05-24 | 개시 | JMP Securities | Mkt Outperform |
| 2021-05-24 | 개시 | Northland Capital | Outperform |
| 2021-01-06 | 개시 | JP Morgan | Overweight |
| 2020-12-16 | 개시 | Piper Sandler | Overweight |
| 2020-09-18 | 재확인 | H.C. Wainwright | Buy |
| 2020-07-15 | 개시 | Jefferies | Buy |
| 2020-05-18 | 재확인 | H.C. Wainwright | Buy |
| 2019-07-08 | 개시 | H.C. Wainwright | Buy |
| 2019-05-09 | 업그레이드 | Stifel | Hold → Buy |
| 2018-12-06 | 개시 | Nomura | Buy |
| 2018-01-29 | 개시 | Stifel | Buy |
| 2017-07-21 | 개시 | BTIG Research | Buy |
모두보기
Protagonist Therapeutics Inc 주식(PTGX)의 최신 뉴스
Protagonist Therapeutics: Promising Pipeline and Strategic Advancements Drive Buy Rating - TipRanks
Protagonist Reports Second Quarter 2025 Financial Results and Provides Corporate Update - The Florida Times-Union
Protagonist Therapeutics Completes Promising Phase 2 Study on PTG-300 for Polycythemia Vera - TipRanks
Protagonist Therapeutics’ Rusfertide Study: A Promising Update for Polycythemia Vera Treatment - TipRanks
Protagonist Therapeutics: Promising Future with Strong Pipeline and Financial Stability - TipRanks
Protagonist Therapeutics price target raised to $69 from $67 at Citizens JMP - TipRanks
Protagonist Therapeutics stock price target raised to $69 by JMP - Investing.com Canada
Protagonist Therapeutics Reports Q2 2025 Results and Pipeline Progress - TipRanks
Protagonist (PTGX) Q2 Revenue Falls 26% - The Motley Fool
Decoding Protagonist Therapeutics Inc (PTGX): A Strategic SWOT I - GuruFocus
Protagonist Therapeutics: Promising Developments in Rusfertide and Icotrokinra Drive Buy Rating - TipRanks
Protagonist Therapeutics earnings beat by $0.03, revenue fell short of estimates - Investing.com Canada
Why Protagonist Therapeutics Shares Are Dropping - TipRanks
Protagonist Therapeutics (PTGX) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Protagonist Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Protagonist Therapeutics: Q2 Earnings Snapshot - San Antonio Express-News
Protagonist Therapeutics Q2 net loss beats expectations - MarketScreener
Protagonist Therapeutics’ Rusfertide Study: Long-term Safety in Focus - TipRanks
Citi Rates Protagonist Therapeutics (PTGX) as Buy Protagonists Drugs Opportunity - MSN
Why is Protagonist Therapeutics Inc. stock attracting strong analyst attentionStay ahead with daily expert stock picks - Jammu Links News
What drives Protagonist Therapeutics Inc. stock priceHigh-octane financial growth - Jammu Links News
Does Protagonist Therapeutics Inc. stock perform well during market downturnsFree Stock Index Interpretation - Jammu Links News
What is Protagonist Therapeutics Inc. company’s growth strategyRapid return acceleration - Jammu Links News
Is it the right time to buy Protagonist Therapeutics Inc. stockAchieve rapid wealth accumulation with smart picks - Jammu Links News
What is the dividend policy of Protagonist Therapeutics Inc. stockUnlock exclusive stock market forecasts - Jammu Links News
Is Protagonist Therapeutics Inc. a growth stock or a value stockTremendous return on equity - Jammu Links News
What are the technical indicators suggesting about Protagonist Therapeutics Inc.Build wealth steadily with proven investment strategies - Jammu Links News
How does Protagonist Therapeutics Inc. compare to its industry peersHigh-octane investment gains - Jammu Links News
What catalysts could drive Protagonist Therapeutics Inc. stock higher in 2025Superior return velocity - Jammu Links News
How strong is Protagonist Therapeutics Inc. company’s balance sheetInvest confidently with professional market insights - Jammu Links News
Protagonist Therapeutics Inc. Stock Analysis and ForecastTriple-digit growth rates - Jammu Links News
What are analysts’ price targets for Protagonist Therapeutics Inc. in the next 12 monthsRapid wealth accumulation - Jammu Links News
How many analysts rate Protagonist Therapeutics Inc. as a “Buy”AI Powered Picks For Fast Growth - Jammu Links News
Protagonist Therapeutics to Host Conference Call to Announce an Oral Obesity Development Candidate - Livingston Daily
What are the latest earnings results for Protagonist Therapeutics Inc.Free Stock Watchlist For Fast Growth - jammulinksnews.com
Protagonist Therapeutics Inc. Company’s Quarterly Earnings Growth: What the Numbers SayConservative Long Term Growth Plans Under Review - metal.it
Will Protagonist Therapeutics Inc. continue its uptrendAI Powered High Return Stock Calls Dominate Watchlists - metal.it
Protagonist Therapeutics Inc. Crosses 200 Day MA — Signal or NoiseHigh Return Stock Focus With Safety Emphasized - metal.it
Protagonist Therapeutics' CEO Insider Sale: Signal or Noise Amid Strong Analyst Optimism? - AInvest
Protagonist Therapeutics Inc. Hits Oversold Level on RSI IndicatorCapital Efficiency Optimized Stock Alerts Reviewed - metal.it
Screener Results Flag Protagonist Therapeutics Inc. as OversoldTarget Return Focused Trade Insights Shared - beatles.ru
Protagonist therapeutics CEO Patel sells $570k in stock By Investing.com - Investing.com Canada
Published on: 2025-07-28 20:33:17 - metal.it
Published on: 2025-07-28 15:35:31 - metal.it
How does Protagonist Therapeutics Inc. generate profit in a changing economyDiscover top stock picks for aggressive growth - Jammu Links News
What are Protagonist Therapeutics Inc. company’s key revenue driversDaily Trading Picks Backed By Experts - Jammu Links News
What institutional investors are buying Protagonist Therapeutics Inc. stockCapitalize on market shifts before others do - Jammu Links News
Protagonist Therapeutics Inc (PTGX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):